+Search query
-Structure paper
Title | Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. |
---|---|
Journal, issue, pages | Mabs, Vol. 11, Page 1175-1190, Year 2019 |
Publish date | Jan 16, 2019 (structure data deposition date) |
Authors | Benschop, R.J. / Chow, C.K. / Tian, Y. / Nelson, J. / Barmettler, B. / Atwell, S. / Clawson, D. / Chai, Q. / Jones, B. / Fitchett, J. ...Benschop, R.J. / Chow, C.K. / Tian, Y. / Nelson, J. / Barmettler, B. / Atwell, S. / Clawson, D. / Chai, Q. / Jones, B. / Fitchett, J. / Torgerson, S. / Ji, Y. / Bina, H. / Hu, N. / Ghanem, M. / Manetta, J. / Wroblewski, V.J. / Lu, J. / Allan, B.W. |
External links | Mabs / PubMed:31181988 |
Methods | X-ray diffraction |
Resolution | 1.914 - 2.14 Å |
Structure data | PDB-6nou: PDB-6nov: |
Chemicals | ChemComp-GOL: ChemComp-HOH: ChemComp-12P: |
Source |
|
Keywords | IMMUNE SYSTEM / IL17 / IL-17 / Ixekizumab / scFv / antibody / Fab |